NSE: NATCOPHARM | BSE: 524816

Strong Performer, Under Radar

Download real time

867.05 -8.05 (-0.92%)

47.10% Fall from 52W High

143.1K NSE+BSE Volume

NSE 23 Jun, 2025 10:08 AM (IST)

15,529.7

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

US FDA Observation

Natco Pharma gets Form 483 with 7 observation from the US FDA for its Pharma facility in Hyderabad See details

Natco Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NATCOPHARM, BSE:524816 Natco Pharma Ltd.

Natco Pharma Ltd.

09 Apr 2018

867.05

-0.92%

Natco Pharma

Buy: Natco Pharma Ltd.

Geojit BNP Paribas

NATCO Pharma (NATCO) is a R&D; focussed, vertically integrated pharmaceutical company with an experienced management team and presence across multiple speciality therapeutic segments. High emphasis on R&D; and complex molecules focusing on long...

Natco Pharma Ltd.'s price crossed below 30Day SMA today

Natco Pharma Ltd.

14 Feb 2018

867.05

-0.92%

Result Update:Natco Pharma

Buy: Natco Pharma Ltd.

Target

Axis Direct

Q3 sales were 16% below expectations on weak India business (down 24% YoY on weak Hep-C sales) and lower-than-expected market share in gCopaxone 40mg (14-15%). However, gross margin was strong at 88% (up 18.6 pp YoY)

Geojit BNP Paribas increased Hold price target of Natco Pharma Ltd. to 952.0 on 11 Jun, 2025.

Natco Pharma Ltd.

09 Feb 2018

867.05

-0.92%

Natco Pharma Ltd Q3FY18 results comment

Results Update: Natco Pharma Ltd.

HDFC Securities

Natco Pharma Ltd Q3FY18 results comment Revenue grew by 31.76% to Rs. 562.2 Cr in Q3FY18 when compared to the previous quarter. On the other hand, it decreased by 16.08% when compared with Q3FY17.

Natco Pharma Ltd. has lost -38.81% in the last 6 Months

Natco Pharma Ltd.

11 Dec 2017

867.05

-0.92%

Natco Pharma Ltd: Limited Competition Specialty Generics in ... (Dec 11, 2017)

Buy: Natco Pharma Ltd.

Target

Karvy

gCopaxone and gTamiflu Provide Significant Opportunity: Natco's partner Mylan launched gCopaxone both 20mg and 40mg. All patents expired for 20mg but 40mg patent litigation is ongoing, thus 40mg is an at-risk launch. The 40mgversion is protected by 5 orange book patents, claims of 4 of these patents were held invalid by District Court and litigation of the fifth patent issued in Aug 2016 was dismissed with prejudice.

Natco Pharma Ltd. is trading below its 30 day SMA of 871.5

Natco Pharma Ltd.

09 Nov 2017

867.05

-0.92%

Result Update:Natco Pharma

Buy: Natco Pharma Ltd.

Target

Axis Direct

Though Q2 revenue declined 9% YoY (on a high base), EBITDA and PAT grew 16% and 27% led by higher-margin limited-competition product gDoxil in US. We expect strong PAT growth of 113% in H2 driven by gCopaxone, gDoxil, gTamiflu OS.

Geojit BNP Paribas increased Hold price target of Natco Pharma Ltd. to 952.0 on 11 Jun, 2025.

Natco Pharma Ltd.

06 Nov 2017

867.05

-0.92%

Natco Pharma Limited

Buy: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 7% YoY to | 427 crore (I-direct estimate: | 496 crore). The revenues were lower than I-direct estimates mainly due to increase in competition in Hep C sales EBITDA margins improved 580 bps YoY to 28.6% (I-direct estimate: 31%) mainly due to a favourable product mix. EBITDA grew 16% to | 122 crore (I-direct estimate: | 154 crore) Adjusted net profit increased 28% YoY to | 85 crore (I-direct...

Natco Pharma Ltd. has an average target of 1297.50 from 4 brokers.

Natco Pharma Ltd.

06 Nov 2017

867.05

-0.92%

Natco Pharmaceuticals Limited - Result Update Q2FY18

Hold: Natco Pharma Ltd.

Recommendation Target

Edelweiss

Natco Pharmaceuticals Limited (NATCO) Q2FY18: Underperformance led by pricing pressure across; exciting launches ahead.

Natco Pharma Ltd. has lost -38.81% in the last 6 Months

Natco Pharma Ltd.

16 Oct 2017

867.05

-0.92%

Company Update:Natco Pharma

Buy: Natco Pharma Ltd.

Axis Direct

Natco's (partner Mylan) 1st generic approval for gCopaxone 40mg (USD 2.9 bn market; possibility of 180 day exclusivity) and 2nd generic approval for gCopaxone 20mg (USD 700 mn market) demonstrate its R&D; ability to execute on complex generics with intricate chemistry and complex processes

Natco Pharma Ltd. has an average target of 1297.50 from 4 brokers.

Natco Pharma Ltd.

12 Oct 2017

867.05

-0.92%

Company Update:Natco Pharma

Buy: Natco Pharma Ltd.

Target

Axis Direct

Natcos (partner Mylan) 1st generic approval for gCopaxone 40mg (USD 2.9 bn market; possibility of 180 day exclusivity) and 2nd generic approval for gCopaxone 20mg (USD 700 mn market) demonstrate its R&D; ability to execute on complex generics with intricate chemistry and complex processes

Natco Pharma Ltd. has lost -38.81% in the last 6 Months

Natco Pharma Ltd.

09 Aug 2017

867.05

-0.92%

Natco Pharmaceuticals Ltd - Result Update Q1FY18

Buy: Natco Pharma Ltd.

Edelweiss

Natco Pharmaceuticals Ltd (NPL) reported a topline of INR 428 crs, which is 5% higher than our estimates. The strong uptick in numbers has been primarily on account of incremental profit...

Geojit BNP Paribas increased Hold price target of Natco Pharma Ltd. to 952.0 on 11 Jun, 2025.

Is Natco Pharma Ltd. worth buying?

541 Votes:

Buy 83.18%

Sell 7.39%

Hold 9.43%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf